Atreca, Inc.
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and t…
Macro
US · Macroeconomic Factors/Risks · ForecastsAtreca, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)
Likelihood Legend A++ is best, F- worst
- A++
- A+
- A
-
Very Unlikely - B+
- B
-
Unlikely
- C+
- C
- D+
- D
- D-
-
Avg.
- E+
- E-
-
Unlikely - F+
- F
- F-
-
Very Unlikely
All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.
All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.